Profit before payment of interest, taxes and amortization: Disc Medicine (IRON)

Brandmark of discmedicine.com (IRON)

Disc Medicine, Inc. (IRON) is accelerating the development of hematological drugs, the success of which depends on FDA approval. Analyzing the EBITDA distribution by period in GURU.Markets, we note that 0.00 reflects the latest value of the metric. The company managed to retain all patients in its trials, and its unique iron regulation method will ensure monopoly status and a high therapy cost in the future.

Disc Medicine (IRON) Profit before payment of interest, taxes and amortization: for the period 11/23/2025 - 11/14/2026

Disc Medicine (IRON) - metric breakdowns and financial figures

- stock price and consensus target price:
Price Chart Disc Medicine Pharma|IRON - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Disc Medicine|IRON - Total Company Value
- business book valuation details:
Net Asset Value per Share Disc Medicine|IRON - Company Book Value|Market-to-Book Ratio discmedicine.com|IRON - Company Total Assets
- debt level and financial liquidity data:
Debt to Equity Ratio Disc Medicine, Inc.|IRON - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Disc Medicine Inc|IRON - Company Aggregate Debts|Debts to Net Assets Disc Medicine|IRON - Company Long-Term Debt|Short-Term Debt Volume Disc Medicine|Quick Liquidity Indicator discmedicine.com
- earnings and market multiples details:
IRON - Net Income|Expected Net Income Disc Medicine, Inc.|IRON - Price to Earnings Ratio|Projected Price to Earnings discmedicine.com|IRON - PEG Multiple|Company Value to EBITDA Disc Medicine|IRON - Operating profit EBITDA|Earnings per share for the last 12 months Disc Medicine|IRON - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months discmedicine.com|IRON - Earnings growth in current year|Expected earnings per share growth for next year Disc Medicine, Inc.
- sales and revenue data:
IRON - Revenue and Sales Volume|Company Future Sales Disc Medicine Pharma|IRON - Price-to-Revenue Ratio|Market Cap to Projected Revenue Disc Medicine
Summary company analytics:IRON Disc Medicine Pharma
Flagship merchandise of Disc Medicine Pharma

Disc Medicine, Inc. is compelled by its status as a scientific pioneer in hematology to maintain high R&D intensity to create unique therapies. The dynamics of EBITDA reflect the business's actual ability to generate cash flow from core operations, allowing investors to assess financial stability and the risk of liquidity shortages through the volatility of this chart.

Competitors of Disc Medicine, Inc. (IRON)

TG Pharma - Profit before payment of interest, taxes and amortization|ACLX - Profit before payment of interest, taxes and amortization|SNDX: Profit before payment of interest, taxes and amortization|Kura Oncology (KURA) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization ADC Therapeutics S.A. (ADCT)|Profit before payment of interest, taxes and amortization Foghorn Therapeutics, Inc.|Profit before interest, taxes and amortization Vor Bio Inc. VOR|Operating profit EBITDA NKTX|coeptistx.com - Operating profit before amortization|Operating profit EBITDA ATNM (Actinium Pharmaceuticals, Inc.)|ESLA: Operating profit before amortization|CASI Pharmaceuticals, Inc - Operating profit EBITDA|Operating income before deduction of amortization Marker Therapeutics MRKR|IN8bio, Inc. (INAB) - Profit before payment of interest, taxes and amortization|ERNA - Operating income before deduction of amortization|GTBP (GT Biopharma) - Operating profit EBITDA|Operating profit before deduction of amortization Aptose (APTO)|Operating profit before deduction of amortization BPTH (Bio-Path)|MEIP (MEI Pharma Corporation) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Vincerx Pharma VINC